Adverse effects reported by participants
| Frequency | Per cent of responses | Per cent of cases | |
| Tinea extension | 145 | 60.17 | 71.08 |
| Tinea exacerbation | 5 | 2.07 | 2.45 |
| Scabies extension | 20 | 8.30 | 9.8 |
| Scabies exacerbation | 1 | 0.41 | 0.49 |
| Acne extension ( | 11 | 4.56 | 5.39 |
| Acne exacerbation | 9 | 3.73 | 4.41 |
| Cushingoid* | 11 | 4.56 | 5.39 |
| Hypertension* | 8 | 3.32 | 3.92 |
| Striae* | 6 | 2.49 | 2.94 |
| Weight gain* | 6 | 2.49 | 2.94 |
| Diabetes* | 5 | 2.07 | 2.45 |
| Other exacerbation † | 5 | 2.07 | 2.45 |
| Other complications ‡ | 9 | 3.73 | 4.41 |
Multiple responses were allowed in this question. Percentages were based on total number of responses. Total number of responses=241. Total number of cases=204.
*Patients used systemic steroids in addition to topical steroids.
†These include lichenification in tinea and chronicity in herpes genitalis
‡These include local cellulitis, topical steroid damaged face (TSDF), telangiectasia, peri oral dermatitis and scabietic nodules